脳腫瘍薬の世界市場レポート 2024

脳腫瘍薬の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には7.1%の年間複合成長率（CAGR）で50億1,000万米ドルに成長すると予想されます。予測される成長は、がん罹患率の上昇、ヘルスケア費の増加、高齢者人口の増加、強力な医薬品パイプライン、生物製剤に対するFDA規制の改訂によるものと考えられます。主な動向としては、脳腫瘍治療のための薬剤の組み合わせへの投資、有効性向上のためのフェーズゼロ臨床試験の採用、有効性を高めるためのドラッグデリバリー技術の利用、細胞および遺伝子治療の拡大への注力、戦略的合併・買収の取り組みなどが挙げられます。

脳腫瘍薬市場の拡大を促進する主なきっかけは、世界規模での神経疾患の蔓延です。これらの障害は、平均寿命の延長、感染症への曝露の増加、座りっぱなしのライフスタイルなどの要因により、ますます蔓延しています。たとえば、全米脳腫瘍協会の報告によると、現在米国では約70万人が原発性脳腫瘍に罹患しており、さらに86,000人が診断を受けると予想されています。脳腫瘍を含む神経疾患を患う人のこの増加は、治療に利用される薬剤の需要の増加に直接寄与しており、それによって脳腫瘍薬市場の成長を促進しています。

化学療法を受ける患者数の急増により、脳腫瘍薬の継続的な拡大が見込まれています。化学療法は、がん細胞などの急速に分裂する細胞を標的にして根絶する強力な薬剤を使用する重要な医療アプローチであり、依然として脳腫瘍の基礎治療です。効果的な化学療法薬の開発と入手しやすさは、治療計画全体の成功に大きく影響します。化学療法の有効性は患者の生存率に大きな影響を与え、生活の質を向上させ、市場情勢に大きな影響を与えます。たとえば、2023年 7月の疾病管理予防センターのデータによると、米国では毎年 100万人を超えるがん患者が化学療法または放射線療法を受けています。その結果、化学療法を選択する患者数の増加は、脳腫瘍薬市場の成長軌道を推進する極めて重要な推進力として機能します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の脳腫瘍薬市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 髄芽腫
• 星状細胞腫
• 希突起膠腫
• 原始神経外胚葉（PNET）
• その他（神経膠腫、聴神経腫、髄膜腫）
• 世界の脳腫瘍薬市場、薬剤別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• テモゾロミド
• カルムスチン
• シスプラチン
• ベバシズマブ
• ゲフチニブ
• エルロチニブ
• 世界の脳腫瘍薬市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院薬局
• クリニック
• その他のエンドユーザー

第7章 地域および国の分析

• 世界の脳腫瘍薬市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
• 世界の脳腫瘍薬市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 脳腫瘍薬市場の競合情勢
• 脳腫瘍薬市場の企業プロファイル
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Amgen Inc.
  • Pfizer Inc.
  • Merck &Co. Inc.

第31章 その他の大手および革新的な企業

• CordenPharma
• Eisai Co., Ltd.
• Emcure Pharmaceuticals Limited
• AstraZeneca
• Y-mAbs Therapeutics
• Roche India
• Novartis Oncology
• Arlak Biotech
• Healthkind Labs Pvt. Ltd.
• SwisscheM Healthcare Pvt.Ltd
• Apikos Pharma
• Kolaz Biotech
• CStone Pharma
• CARsgen Therapeutics
• JW Therapeutics

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Brain tumor drugs are medications utilized in the treatment of brain tumors, employing a range of approaches including chemotherapy, hormone therapies, anticonvulsants, and painkillers. While certain prescription drugs aim to manage symptoms during tumor treatment, chemotherapy specifically targets the reduction or destruction of brain tumors.

Key drugs in the realm of brain tumor treatment include temozolomide, carmustine, cisplatin, bevacizumab, gefitinib, and erlotinib. Temozolomide, for instance, is designed to treat specific types of brain cancer such as glioblastomamultiforme and anaplastic astrocytoma. These drugs fall under the category of antineoplastics, focusing on combating cancer. Various types of brain tumors, such as medulloblastoma, astrocytoma, oligodendroglioma, primitive neuroectodermal (PNET), and others such as glioma, acoustic neuroma, and meningioma, are addressed using these drugs. The sectors benefiting from these treatments include hospital pharmacies, clinics, and other healthcare facilities.

The brain tumor drugs market research report is one of a series of new reports from The Business Research Company that provides brain tumor drugs market statistics, including brain tumor drugs industry global market size, regional shares, competitors with a brain tumor drugs market share, detailed brain tumor drugs market segments, market trends and opportunities, and any further data you may need to thrive in the brain tumor drugs industry. This brain tumor drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The brain tumor drugs market size has grown strongly in recent years. It will grow from $3.55 billion in 2023 to $3.81 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The historical growth can be attributed to several factors, including a rising prevalence of neurological disorders, increased healthcare expenditure, a higher number of approvals for oncology (cancer) drugs, an upsurge in pharmaceutical research and development (R&D) expenditure, and advancements in cancer drug discovery.

The brain tumor drugs market size is expected to see strong growth in the next few years. It will grow to $5.01 billion in 2028 at a compound annual growth rate (CAGR) of 7.1%. Forecasted growth is attributed to rising cancer rates, increased healthcare spending, a growing elderly population, a robust drug pipeline, and revised FDA regulations for biologics. Major trends include investing in drug combinations for brain tumor treatment, adopting phase zero clinical trials for efficacy improvement, using technology in drug delivery for enhanced effectiveness, focusing on expanding cell and gene therapy, and engaging in strategic mergers and acquisitions.

The primary catalyst fueling the expansion of the Brain Tumor drugs market is the escalating prevalence of Neurological Disorders on a global scale. These disorders have become increasingly prevalent due to factors such as longer life expectancy, heightened exposure to infections, and sedentary lifestyles. For instance, as reported by the National Brain Tumor Society, approximately 700,000 individuals in the United States are currently affected by primary brain tumors, with an additional 86,000 expected to receive diagnoses. This growing population of individuals with neurological disorders, including brain tumors, is directly contributing to the increased demand for drugs utilized in their treatment, thereby fostering the growth of the brain tumor drugs market.

The surge in the number of patients undergoing chemotherapy is poised to drive the continued expansion of brain tumor drugs. Chemotherapy, a vital medical approach employing potent drugs to target and eradicate rapidly dividing cells such as cancer cells, remains a cornerstone treatment for brain tumors. The development and accessibility of effective chemotherapy drugs significantly influence the overall success of treatment regimens. The efficacy of chemotherapy profoundly impacts patient survival rates and enhances their quality of life, exerting a substantial influence on the market landscape. For instance, based on data from the Centers for Disease Control and Prevention in July 2023, over 1 million cancer patients in the United States undergo chemotherapy or radiation therapy annually. Consequently, the escalating number of patients opting for chemotherapy serves as a pivotal driver propelling the growth trajectory of the brain tumor drugs market.

Companies within the brain tumor drugs market are increasingly turning towards nanotechnology for treatment methodologies. Nanoparticles are being utilized as carriers for drugs, delivering them directly to cancer cells or into the tumor, yielding advantages such as reduced drug dosage, enhanced shelf life, and minimized toxicity. Some nanodrugs have proven effective in surmounting the blood-brain barrier, a historically significant challenge in treating brain tumors. Notably, nanoparticles such as Liposomes have facilitated targeted drug delivery to the core of cancer cells. Moreover, when coated with transferrin, these particles can breach the blood-brain barrier. Esteemed industry players such as GE Healthcare, Sigma-Tau Pharmaceuticals Inc., Johnson & Johnson, Merck & Company Inc., Pfizer, Inc., and Celgene Corporation are actively embracing this technology to advance medication and treatment techniques.

Key industry entities within the brain tumor drugs market are heavily invested in the development and approval of novel drugs, aiming to gain a competitive advantage. Drug approvals represent the regulatory process by which government health agencies authorize the marketing, sale, and prescription of new medications for specific medical conditions. For example, in June 2022, the United States Food and Drug Administration granted accelerated approval for a novel treatment combination incorporating the oral drugs dabrafenib (Tafinlar) and trametinib (Mekinist) for advanced brain tumors exhibiting the BRAF V600E mutation. This approval extends to both adult and pediatric patients with high- and low-grade gliomas that have progressed post-prior treatments. Encouraging results from clinical trials revealed significant tumor reduction among patients receiving the combination therapy. Notably, positive responses were observed in 33% of high-grade glioma patients, 50% of low-grade glioma patients, and 25% of pediatric glioma patients. The BRAF V600E mutation is prevalent across various glioma types, including low-grade gliomas, pleomorphic xanthoastrocytomas (PXA), gangliogliomas, and pilocytic astrocytomas.

In December 2021, Sanofi, a French pharmaceutical company, completed the acquisition of Amunix Pharmaceuticals Inc. for a total of $1 billion. This strategic move positions Sanofi to advance its efforts in developing potentially transformative cancer therapies, particularly in the field of immuno-oncology. Amunix Pharmaceuticals Inc., a U.S.-based pharmaceutical company, brings valuable assets, including brain tumor drugs, to bolster Sanofi's capabilities in the oncology space.

Major companies operating in the brain tumor drugs market report are F. Hoffmann-La Roche Ltd., Novartis AG, Amgen Inc., Pfizer Inc., Merck & Co. Inc., CordenPharma, Eisai Co., Ltd., Emcure Pharmaceuticals Limited, AstraZeneca, Y-mAbs Therapeutics, Roche India, Novartis Oncology, Arlak Biotech, Healthkind Labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd., Apikos Pharma, Kolaz Biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals (Japan), Astellas Pharma Inc., Otsuka Pharmaceutical Co., Ltd., Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, Baxter International Inc. (UK), AstraZeneca PLC, GlaxoSmithKline PLC, F. Hoffmann-La Roche AG, Veropharm, Biocad, Bristol-Myers Squibb, Celon Pharma, Celgene Corporation, Johnson & Johnson, Eli Lilly and Company, Sandoz AG, Eurofarma Laboratorios S.A., TUTEUR Argentina, The Takeda Pharmaceutical Company Limited, Pierre Fabre Group, Celnova Pharma, Pfizer S.R.L., Teva Pharmaceutical Industries Ltd., BIOPHARMA-MEA, NeoTX, AID Genomics Limited, GlaxoSmithKline PLC, Julphar, Sanofi, Novo Nordisk A/S, Bayer, Kitov Pharma Limited, CureTech Ltd., Neopharma, Eurolab, Aspen, Adcock Ingram.

North America was the largest region in the brain tumor drugs market in 2023. Middle East is expected to be the fastest-growing region in the global brain tumor drugs market share during the forecast period. The regions covered in the brain tumor drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the brain tumor drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The brain tumor drugs market consists of sales Afinitor (Everolimus), Afinitor Disperz (Everolimus), Belzutifan, and Bevacizumab. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Brain Tumor Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on brain tumor drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for brain tumor drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The brain tumor drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Drugs: Temozolomide; Bevacizumab; Other Drugs
• 2) By End User: Hospital Pharmacies; Retail Pharmacies/Drug Stores; Other End-Users
• Companies Mentioned: F. Hoffmann-La Roche Ltd; Novartis AG; Amgen Inc.; Pfizer Inc.; Merck & Co. Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Brain Tumor Drugs Market Characteristics

3. Brain Tumor Drugs Market Trends And Strategies

4. Brain Tumor Drugs Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Brain Tumor Drugs Market Size and Growth

• 5.1. Global Brain Tumor Drugs Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Brain Tumor Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Brain Tumor Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Brain Tumor Drugs Market Segmentation

• 6.1. Global Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Medulloblastoma
• Astrocytoma
• Oligodendroglioma
• Primitive Neuroectodermal (PNET)
• Others (Glioma, Acoustic Neuroma, Meningioma)
• 6.2. Global Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Temozolomide
• Carmustine
• Cisplatin
• Bevacizumab
• Geftinib
• Erlotinib
• 6.3. Global Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacies
• Clinics
• Other End-Users

7. Brain Tumor Drugs Market Regional And Country Analysis

• 7.1. Global Brain Tumor Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Brain Tumor Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Brain Tumor Drugs Market

• 8.1. Asia-Pacific Brain Tumor Drugs Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Brain Tumor Drugs Market

• 9.1. China Brain Tumor Drugs Market Overview
• 9.2. China Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Brain Tumor Drugs Market

• 10.1. India Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Brain Tumor Drugs Market

• 11.1. Japan Brain Tumor Drugs Market Overview
• 11.2. Japan Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Brain Tumor Drugs Market

• 12.1. Australia Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Brain Tumor Drugs Market

• 13.1. Indonesia Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Brain Tumor Drugs Market

• 14.1. South Korea Brain Tumor Drugs Market Overview
• 14.2. South Korea Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Brain Tumor Drugs Market

• 15.1. Western Europe Brain Tumor Drugs Market Overview
• 15.2. Western Europe Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Brain Tumor Drugs Market

• 16.1. UK Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Brain Tumor Drugs Market

• 17.1. Germany Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Brain Tumor Drugs Market

• 18.1. France Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Brain Tumor Drugs Market

• 19.1. Italy Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Brain Tumor Drugs Market

• 20.1. Spain Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Brain Tumor Drugs Market

• 21.1. Eastern Europe Brain Tumor Drugs Market Overview
• 21.2. Eastern Europe Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Brain Tumor Drugs Market

• 22.1. Russia Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Brain Tumor Drugs Market

• 23.1. North America Brain Tumor Drugs Market Overview
• 23.2. North America Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Brain Tumor Drugs Market

• 24.1. USA Brain Tumor Drugs Market Overview
• 24.2. USA Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Brain Tumor Drugs Market

• 25.1. Canada Brain Tumor Drugs Market Overview
• 25.2. Canada Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Brain Tumor Drugs Market

• 26.1. South America Brain Tumor Drugs Market Overview
• 26.2. South America Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Brain Tumor Drugs Market

• 27.1. Brazil Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Brain Tumor Drugs Market

• 28.1. Middle East Brain Tumor Drugs Market Overview
• 28.2. Middle East Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Brain Tumor Drugs Market

• 29.1. Africa Brain Tumor Drugs Market Overview
• 29.2. Africa Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Brain Tumor Drugs Market Competitive Landscape And Company Profiles

• 30.1. Brain Tumor Drugs Market Competitive Landscape
• 30.2. Brain Tumor Drugs Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Novartis AG
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Amgen Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Pfizer Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Merck & Co. Inc.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Brain Tumor Drugs Market Other Major And Innovative Companies

• 31.1. CordenPharma
• 31.2. Eisai Co., Ltd.
• 31.3. Emcure Pharmaceuticals Limited
• 31.4. AstraZeneca
• 31.5. Y-mAbs Therapeutics
• 31.6. Roche India
• 31.7. Novartis Oncology
• 31.8. Arlak Biotech
• 31.9. Healthkind Labs Pvt. Ltd.
• 31.10. SwisscheM Healthcare Pvt.Ltd
• 31.11. Apikos Pharma
• 31.12. Kolaz Biotech
• 31.13. CStone Pharma
• 31.14. CARsgen Therapeutics
• 31.15. JW Therapeutics

32. Global Brain Tumor Drugs Market Competitive Benchmarking

33. Global Brain Tumor Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Brain Tumor Drugs Market

35. Brain Tumor Drugs Market Future Outlook and Potential Analysis

• 35.1 Brain Tumor Drugs Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Brain Tumor Drugs Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Brain Tumor Drugs Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer